Literature DB >> 36169450

Left Atrial Thrombus and Dense Spontaneous Contrast in Direct Oral Anticoagulant Therapy of Atrial Fibrillation: Insights from a Reference Center.

Thiago Marques1, Francisco Darrieux1, Fábio Gouvêa1, Leandro Garambone1, Ana Paula Lindoso1, João Lage1, Luciana Sacilotto1, Ana Lúcia Coimbra1, Martina Pinheiro1, Natália Olivetti1, Sissy Lara1, Carina Hardy1, Guilherme Athayde1, Denise Hachul1, Cristiano Pisani1, Tan Chen Wu1, Maurício Scanavacca1.   

Abstract

BACKGROUND: In the treatment of atrial fibrillation (AF), the most frequently sustained arrhythmia, with catheter ablation (CA) or electrical cardioversion (ECV), the periprocedural period is one of the most critical phases. Currently, the use of new direct action oral anticoagulants (DOAC) is increasingly frequent; however, in the real world, there are still few data on studies on the thrombus incidence in the left atrium (TrLA) or dense spontaneous contrast (DSC) on transesophageal echocardiogram (TEE).
OBJECTIVE: To evaluate the prevalence of events and association with risk factors in patients using DOACs. Primary objective: to analyze the prevalence of thrombus in the LA by TEE in patients using DOAC undergoing ECV/CA. Second, evaluate the association of comorbidities with the presence of thrombi and DSC.
METHODS: Retrospective cohort, single-center study with patients followed at the Arrhythmia Outpatient Unit (InCor-HCFMUSP). Patients indicated for procedures and using DOACs were selected, and their clinical/echocardiographic data were analyzed. A significance level of 5% was considered.
RESULTS: 354 patients were included, a total of 400 procedures, from March 2012-March 2018. Thrombus in the LA was found in 11 patients (2.8%), associated with advanced age (p=0.007) and higher CHA2DS2-VASc (p<0.001) score. DSC in the LA before TEE was found in 29 patients (7.3%), with lower LVEF (p<0.038) and greater LA dimension (p<0.0001).
CONCLUSION: The incidence of LA thrombus and DSC in patients using DOC in the context of AF ECV/CA, although small, is not negligible. Patients with higher CHA2DS2-VASc scores, especially older and with larger LA diameter, are more prone to these echocardiographic findings.

Entities:  

Year:  2022        PMID: 36169450      PMCID: PMC9563890          DOI: 10.36660/abc.20210658

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.667


  20 in total

Review 1.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

2.  Prevalence and Clinical Determinants of Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation Before Pulmonary Vein Isolation.

Authors:  Makiko Nishikii-Tachibana; Nobuyuki Murakoshi; Yoshihiro Seo; DongZhu Xu; Masayoshi Yamamoto; Tomoko Ishizu; Akiko Atsumi; Tomoko Machino-Ohtsuka; Kenji Kuroki; Hiro Yamasaki; Miyako Igarashi; Yukio Sekiguchi; Kazutaka Aonuma
Journal:  Am J Cardiol       Date:  2015-08-14       Impact factor: 2.778

Review 3.  Assessment and Management of the Left Atrial Appendage Thrombus in Patients With Nonvalvular Atrial Fibrillation.

Authors:  Yang Zhan; Jacqueline Joza; Mohamed Al Rawahi; Rodrigo S Barbosa; Michelle Samuel; Martin Bernier; Thao Huynh; George Thanassoulis; Vidal Essebag
Journal:  Can J Cardiol       Date:  2017-12-15       Impact factor: 5.223

4.  Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).

Authors:  Greg Flaker; Renato D Lopes; Sana M Al-Khatib; Antonio G Hermosillo; Stefan H Hohnloser; Brian Tinga; Jun Zhu; Puneet Mohan; David Garcia; Jozef Bartunek; Dragos Vinereanu; Steen Husted; Veli Pekka Harjola; Marten Rosenqvist; John H Alexander; Christopher B Granger
Journal:  J Am Coll Cardiol       Date:  2013-11-06       Impact factor: 24.094

5.  Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation.

Authors:  Sarinya Puwanant; Brandon C Varr; Kevin Shrestha; Sarah K Hussain; W H Wilson Tang; Ruvin S Gabriel; Oussama M Wazni; Mandeep Bhargava; Walid I Saliba; James D Thomas; Bruce D Lindsay; Allan L Klein
Journal:  J Am Coll Cardiol       Date:  2009-11-24       Impact factor: 24.094

6.  Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.

Authors:  Jonathan P Piccini; Susanna R Stevens; Yuliya Lokhnygina; Manesh R Patel; Jonathan L Halperin; Daniel E Singer; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Günter Breithardt
Journal:  J Am Coll Cardiol       Date:  2013-03-14       Impact factor: 24.094

7.  Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.

Authors:  Christoph Stellbrink; Uwe Nixdorff; Thomas Hofmann; Walter Lehmacher; Werner Günther Daniel; Peter Hanrath; Christoph Geller; Andreas Mügge; Walter Sehnert; Caroline Schmidt-Lucke; Jan-André Schmidt-Lucke
Journal:  Circulation       Date:  2004-02-16       Impact factor: 29.690

8.  Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.

Authors:  Michael Wu; James Gabriels; Mohammad Khan; Nada Shaban; Salvatore D'Amato; Christopher F Liu; Steven M Markowitz; James E Ip; George Thomas; Parmanand Singh; Bruce Lerman; Apoor Patel; Jim W Cheung
Journal:  Heart Rhythm       Date:  2018-04       Impact factor: 6.343

9.  Prevalence of left atrial appendage thrombus detected by transoesophageal echocardiography before catheter ablation of atrial fibrillation in patients anticoagulated with non-vitamin K antagonist oral anticoagulants.

Authors:  Wael Alqarawi; David H Birnie; Stewart Spence; F Daniel Ramirez; Calum J Redpath; Robert Lemery; Girish M Nair; Pablo B Nery; Darryl R Davis; Martin S Green; Luc Beauchesne; Kwan Chan; Kathryn Ascah; Ian Burwash; Mouhannad M Sadek
Journal:  Europace       Date:  2019-01-01       Impact factor: 5.214

10.  Incidence and Predictors of Intracardiac Thrombus on Pre-electrophysiological Procedure Transesophageal Echocardiography.

Authors:  Mohamed Al Rawahi; Michelle Samuel; Christos Galatas; Jacqueline Joza; Pedro Y Lima; Rodrigo Barbosa; George Thanassoulis; Martin L Bernier; Thao Huynh; Vidal Essebag
Journal:  CJC Open       Date:  2019-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.